Recipharm increases lyophilisation capacity in Italy
Recipharm, the contract development and manufacturing organisation (CDMO), has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demand.
The investment forms part of Recipharm’s strategy to become a leading lyophilisation provider, and is in addition to the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32 million is currently being spent to increase capacity.
Specialising in aseptic manufacturing and filling of parenterals, Recipharm in Masate, located close to Milan, offers lyophilisation capabilities in both vials and ampoules. The investment will see the introduction of a new lyophiliser for vials, bringing the total number of machines from five to six and increasing the facility’s capacity by approximately 20 per cent.
The new machine will allow the CDMO to support more drug developers with their stability challenges and meet growing demand for its lyophilisation services, particularly in Europe, China and Japan.
Commenting on the investment, General Manager Giorgio Bruno said: “We are experiencing greater demand for lyophilisation capabilities from our customers, ranging from some of the largest pharmaceutical companies to small and mid-sized firms. As we continue to receive more requests from existing customers and new enquiries from drug developers in new territories, we needed to increase our capacity”.
Giorgio Bruno, General Manager, email@example.com, +39 3358100229
Kjell Johansson, President Manufacturing Services Europe, firstname.lastname@example.org, + 46 739 622620
For media enquiries, please contact Lindsay Baldry at ramarketing: email@example.com,
+ 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr,
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and its services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03